Organon Revenue and Competitors
Estimated Revenue & Valuation
- Organon's estimated annual revenue is currently $7.9B per year.
- Organon's estimated revenue per employee is $789,658
- Organon's current valuation is $8.3B. (January 2022)
Employee Data
- Organon has 9979 Employees.
- Organon grew their employee count by 5% last year.
Organon's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Director, CEO Communications | Reveal Email/Phone |
4 | Chief Staff to the CEO and head Corporate Strategy | Reveal Email/Phone |
5 | Chief Staff to the General Counsel | Reveal Email/Phone |
6 | CIO | Reveal Email/Phone |
7 | Executive Director Business Development | Reveal Email/Phone |
8 | Head Corporate Strategy & Chief Staff | Reveal Email/Phone |
9 | Chief Ethics & Compliance Officer | Reveal Email/Phone |
10 | Chief Procurement Officer | Reveal Email/Phone |
Organon Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Organon?
Organon is a Dutch pharmaceutical company started in Oss the Netherlands. It is famous for "the Pil" a birthcontrol pil. Organon grew as a company and was taken over by Schering plough and later on by Merck and continues as MSD in the Netherlands. In the old days the compant was great, it used to be "gezellig" !
keywords:N/A
N/A
Total Funding
9979
Number of Employees
$7.9B
Revenue (est)
5%
Employee Growth %
$8.3B
Valuation
N/A
Accelerator
Organon News
JERSEY CITY, N.J.--(BUSINESS WIRE)--Apr 21, 2022--. Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5,...
Organon & Co. (NYSE:OGN) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...
Organon Enters into Global License Agreement to Commercialize Daré Bioscience's XACIATO (clindamycin phosphate vaginal gel, 2%), FDA-Approved...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $75M | 10057 | 4% | N/A |
#2 | $4687.9M | 10303 | N/A | N/A |
#3 | $1676.8M | 10506 | 13% | N/A |
#4 | $4837.2M | 10534 | -3% | N/A |
#5 | $750M | 10716 | 2% | N/A |